• GAVI newsletter signup

    See previous newsletters

  • @GAVIAlliance Twitter feed

  • Mid-Term Review meeting

    Mid-Term Review meeting

    More information on upcoming meeting in Stockholm, Sweden

  • Audio-visual updates

    16 December 2013

    Burundi launches a new vaccine against rotavirus diarrhoea

    Burundi became on December 16, 2013 the 19th GAVI eligible country to introduce in its routine immunisation programme antirotavirus vaccine. Rotavirus is the leading cause of severe and often fatal diarrhoea among under five children. In Burundi, diarrhoea causes approximately 15 percent of deaths in children less than five years of age. By 2015, GAVI with the support of its donors and partners plan to support the introduction of this vaccine in more than 30 countries.

    11 December 2013

    Animation: Why Invest in Vaccines

    Vaccines do far more than protect health; they also protect people’s incomes and savings, and promote economic growth. Find out how.

    27 November 2013

    GAVI supported rotavirus vaccines introduced in Zambia

    Following a successful pilot program delivering rotavirus vaccines as part of an integrated approach to diarrhoea prevention and control, in November 2013, Zambia rolled out GAVI-supported rotavirus vaccines nationwide. Rotavirus, the most common cause of severe and fatal diarrhoea in young children worldwide, takes the lives of over 3,600 Zambian children under five each year and accounts for approximately 40 percent of all under-five diarrhoeal deaths and hospitalisations. Zambia is the 18th GAVI-eligible country to introduce rotavirus vaccines in its national immunisation program. (credit VITAC-PATH)

    19 November 2013

    GAVI Alliance: Supporting Cambodia's immunisation programme

    In this three-minute film, GAVI Alliance partners in Cambodia including the Health Minister, health workers and representatives from UNICEF and the World Health Organization explain how GAVI's support is boosting routine immunisation coverage and campaigns against diseases like measles and rubella. First shown at the GAVI Alliance Board meeting in Phnom Penh in November 2013.

  • Value of vaccination

    Vaccines are cost-effective, offer lifelong protection and are fundamental to development.

  • GAVI's impact

    GAVI's impact feature

    "The GAVI model" has contributed to the immunisation of an additional 440 million children, averting approximately six million future deaths.

close icon

modal window here